& Gilbert, S
Myth: Taking levothyroxine and semaglutide together is dangerous
Recent Major Changes Indications and Usage for Vyvanse VYVANSE is a central nervous system (CNS) stimulant indicated for the treatment of (1): Attention Deficit Hyperactivity Disorder (ADHD) in adults and pediatric patients 6 years and older Moderate to severe binge eating disorder (BED) in adults Limitations of Use: The use of VYVANSE is not recommended in pediatric patients younger than 6 years of age because they had higher plasma exposure and a higher incidence of adverse reactions (e.g., weight loss) than patients 6 years and older at the same dosage (5.5, 8.4) VYVANSE is not indicated for weight loss
trial participants should contact their trial team, and anyone experiencing severe symptoms should call 999 or attend A&E immediately
More serious risks include pancreatitis, gallbladder disease, acute kidney injury from dehydration, and hypoglycemia (when used with insulin or sulfonylureas)
Topamax inhibits carbonic anhydrase, which can lead to metabolic acidosis and increased risk of kidney stones, whilst Ozempic's gastrointestinal effects may lead to dehydration if vomiting or diarrhoea is severe
